1-10 of 10
Delia Rota Scalabrini, Md
Close
Sort by
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Francesca Gay, MD, Chiara Cerrato, MD, Delia Rota Scalabrini, MD, Monica Galli, MD, Angelo Belotti, MD, Elena Zamagni, MD, Antonio Ledda, MD, Mariella Grasso, MD, Emanuele Angelucci, MD, Anna Marina Liberati, MD, Patrizia Tosi, MD, Francesco Pisani, MD, Stefano Spada, Ombretta Annibali, MD, Anna Baraldi, MD, Paola Omedé, Piero Galieni, MD, Rita Rizzi, MD, Norbert Pescosta, MD, Sonia Ronconi, MD, Donatella Vincelli, MD, Anna Maria Cafro, MD, Massimo Offidani, MD, Antonio Palumbo, MD, Pellegrino Musto, MD, Michele Cavo, MD, Mario Boccadoro, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 121.
https://doi.org/10.1182/blood-2018-99-112093
Published: 2018
Journal Articles

Low Circulating B Lymphocytes in Newly Diagnosed Follicular and Diffuse Large B Cell Lymphoma: Differences Compared to Normal Subjects and Possible Prognostic Role

Riccardo Bruna, Massimo Geuna, Delia Rota Scalabrini, MD, Alessandro Cignetti, MD PhD, Nathalie Santoro, Daniela Gottardi, MD, Roberto Passera, Corrado Tarella, MD Prof
Journal: Blood
Blood (2017) 130 (Supplement 1): 1482.
https://doi.org/10.1182/blood.V130.Suppl_1.1482.1482
Published: 2017
Journal Articles

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Francesca Maria Gay, Delia Rota Scalabrini, MD, Angelo Belotti, MD, Monica Galli, MD PhD, Elena Zamagni, MD, Massimo Offidani, MD, Stefania Oliva, MD, Vittorio Montefusco, MD, Renato Zambello, MD, Antonio Ledda, MD, Mariella Grasso, MD, Sara Aquino, MD, Fabrizio Esma, Patrizia Tosi, MD, Francesco Pisani, MD, Ombretta Annibali, Anna Marina Liberati, Anna Baraldi, MD, Piero Galieni, MD, Giorgina Specchia, MD, Norbert Pescosta, MD, Katia Mancuso, MD, Laura Paris, MD, Rossella Ribolla, MD, Valentina Coha, MD, Antonio Palumbo, MD, Pellegrino Musto, MD, Michele Cavo, MD, Mario Boccadoro
Journal: Blood
Blood (2017) 130 (Supplement 1): 4541.
https://doi.org/10.1182/blood.V130.Suppl_1.4541.4541
Published: 2017
Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Corrado Tarella, MD, Fabio Benedetti, MD, Carola Boccomini, MD, Caterina Patti, MD, Anna Maria Barbui, MD, Alessandro Pulsoni, MD, Maurizio Musso, Anna Marina Liberati, Guido Gini, MD, Claudia Castellino, Fausto Rossini, Fabio Ciceri, M.D., Delia Rota Scalabrini, MD, Caterina Stelitano, Francesco Di Raimondo, MD, Tommasina Perrone, Alessandra Tucci, Atto Billio, MD, Francesco Zallio, MD, Valerio Zoli, MD, Angela Congiu, Franco Narni, MD, Alessandra Dondi, Guido Parvis, MD, Gianpietro Semenzato, MD, Paolo Corradini, Riccardo Bruna, MD, Angela Gueli, MD, Barbara Mantoan, Roberto Passera, Michele Magni, MD, Marco Ladetto
Journal: Blood
Blood (2013) 122 (21): 551.
https://doi.org/10.1182/blood.V122.21.551.551
Published: 2013
Journal Articles

Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma

Antonio Palumbo, MD, Alessandra Larocca, MD, Vittorio Montefusco, Davide Rossi, MD, PhD, Angelo Michele Carella, MD, Roberto Mina, MD, Claudia Crippa, MD, Mariella Sciacca, MD, Monica Galli, MD, Delia Rota Scalabrini, MD, Magda Marcatti, MD, Tommasina Guglielmelli, MD, Nicola Giuliani, Giacinto La Verde, MD, Ileana Baldi, MD, Vittorio Emanuele Muccio, Mario Boccadoro, MD, Paolo Corradini, MD
Journal: Blood
Blood (2012) 120 (21): 446.
https://doi.org/10.1182/blood.V120.21.446.446
Published: 2012
Journal Articles

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Marco Ladetto, MD, Chiara Lobetti-Bodoni, MD, Barbara Mantoan, Ph.D, Andrea Evangelista, Carola Boccomini, MD, Elisa Genuardi, Ph.D, Barbara Botto, Luca Baldini, MD, Giuseppe Rossi, MD, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, MD, Antonello Pinto, MD, Mario Petrini, M.D., Ph.D., Stefano Sacchi, Delia Rota-Scalabrini, MD, Luigi Gugliotta, MD, Renato Fanin, MD, Andrea Gallamini, MD, Guido Parvis, MD, Giorgina Specchia, Pellegrino Musto, MD, Barbara Olivero, MD, Enrica Gamba, MD, Giovannino Ciccone, MD, Umberto Vitolo
Journal: Blood
Blood (2012) 120 (21): 787.
https://doi.org/10.1182/blood.V120.21.787.787
Published: 2012
Journal Articles

Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.

Marco Ladetto, MD, Federica De Marco, MD, Fabio Benedetti, MD, Umberto Vitolo, MD, Caterina Patti, MD, Alessandro Rambaldi, MD, Alessandro Pulsoni, MD, Maurizio Musso, MD, Anna M. Liberati, MD, Attilio Olivieri, MD, Andrea Gallamini, MD, Enrico Pogliani, MD, Delia Rota Scalabrini, MD, Vincenzo Callea, MD, Francesco Di Raimondo, MD, Vincenzo Pavone, MD, Alessandra Tucci, MD, Sergio Cortelazzo, MD, Alessandro Levis, MD, Mario Boccadoro, MD, Ignazio Majolino, MD, Alessandro Pileri, MD, Alessandro M. Gianni, MD, Roberto Passera, PhD, Paolo Corradini, MD, Corrado Tarella, MD
Journal: Blood
Blood (2007) 110 (11): 20.
https://doi.org/10.1182/blood.V110.11.20.20
Published: 2007
Journal Articles

ABVD Versus VEPEMB in Elderly Hodgkin’s Lymphoma Patients.

Alessandro Levis, MD, Francesco Merli, Md, Stefania Tamiazzo, PhD, Annalisa Arcari, Md, Monica Bellei, PhD, Maura Brugiatelli, Md, Massimo Federico, Md, Marina Liberati, Md, Giovanni Partesotti, Md, Patrizia Pregno, Md, Delia Rota Scalabrini, Md, Daniele Sabiu, Md, Flavia Salvi, Md, Caterina Stelitano, Md
Journal: Blood
Blood (2007) 110 (11): 2322.
https://doi.org/10.1182/blood.V110.11.2322.2322
Published: 2007
Journal Articles

Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.

Marco Ladetto, MD, Federica de Marco, MD, Fabio Benedetti, MD, Umberto Vitolo, MD, Caterina Patti, MD, Alessandro Rambaldi, MD, Anna Marina Liberati, MD, Maurizio Musso, MD, Alessandro Pulsoni, MD, Attilio Olivieri, MD, Enzo Pavone, MD, Enrico Pogliani, MD, Delia Rota Scalabrini, MD, Andrea Gallamini, MD, Vincenzo Callea, MD, Irene Ricca, MD, Mario Boccadoro, MD, Ignazio Majolino, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2006) 108 (11): 325.
https://doi.org/10.1182/blood.V108.11.325.325
Published: 2006
Journal Articles

Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.

Marco Ladetto, MD, Irene Ricca, MD, Fabio Benedetti, MD, Umberto Vitolo, MD, Caterina Patti, MD, Alessandro Rambaldi, MD, Anna Marina Liberati, MD, Maurizio Musso, MD, Alessandro Pulsoni, MD, Attilio Olivieri, MD, Enzo Pavone, MD, Enrico Pogliani, MD, Delia Rota Scalabrini, MD, Andrea Gallamini, MD, Vincenzo Callea, MD, Barbara Mantoan, PhD, Mario Boccadoro, MD, Ignazio Majolino, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2005) 106 (11): 675.
https://doi.org/10.1182/blood.V106.11.675.675
Published: 2005